Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker for diagnosis of pleural mesothelioma (PM) and the most used for monitoring treatment. Radiological assessment of PM, based on modified RECIST (mRECIST) criteria, is challenging. This pilot study was designed to evaluate...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/11/2015 |
| _version_ | 1827676859047870464 |
|---|---|
| author | Federica Grosso Matilde Mannucci Francesca Ugo Paola Ferro Maurizio Cassinari Antonella Vigani Antonina Maria De Angelis Sara Delfanti Michela Lia Roberto Guaschino Stefano Barbero Silvio Roncella Ugo Giannoni Marinella Bertolotti Maria Pia Pistillo Vincenzo Fontana |
| author_facet | Federica Grosso Matilde Mannucci Francesca Ugo Paola Ferro Maurizio Cassinari Antonella Vigani Antonina Maria De Angelis Sara Delfanti Michela Lia Roberto Guaschino Stefano Barbero Silvio Roncella Ugo Giannoni Marinella Bertolotti Maria Pia Pistillo Vincenzo Fontana |
| author_sort | Federica Grosso |
| collection | DOAJ |
| description | A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker for diagnosis of pleural mesothelioma (PM) and the most used for monitoring treatment. Radiological assessment of PM, based on modified RECIST (mRECIST) criteria, is challenging. This pilot study was designed to evaluate whether SMRP levels correlated over time with mRECIST score. Serial serum samples from PM patients were collected and SMRP levels were measured and compared with the mRECIST score obtained through centralized CT scans by blinded review. The within-patient SMRP-mRECIST relationship over time was estimated through a normal random-effects regression approach applied to the log-transformed mRECIST score. Overall, 58 PM patients were included (46 males and 12 females) with a median age at diagnosis of 67 years (min–max = 48–79), 44 (76%) with epithelioid and 14 (24%) with non-epithelioid histology. The total number of SMRP measurements and CT scans considered for analysis was 183. There was a statistically significant correlation between SMRP and mRECIST score in the 2 cohorts considered both separately and jointly. These results, although exploratory, suggest that SMRP measurement might be considered as an adjunct to monitor PM patients in order to delay CT scans time interval, thus warranting further investigation. |
| first_indexed | 2024-03-10T05:34:10Z |
| format | Article |
| id | doaj.art-28405c6350474f358c3d863dfe112cdc |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T05:34:10Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-28405c6350474f358c3d863dfe112cdc2023-11-22T23:01:07ZengMDPI AGDiagnostics2075-44182021-10-011111201510.3390/diagnostics11112015Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST ScoreFederica Grosso0Matilde Mannucci1Francesca Ugo2Paola Ferro3Maurizio Cassinari4Antonella Vigani5Antonina Maria De Angelis6Sara Delfanti7Michela Lia8Roberto Guaschino9Stefano Barbero10Silvio Roncella11Ugo Giannoni12Marinella Bertolotti13Maria Pia Pistillo14Vincenzo Fontana15Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyClinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyInfrastruttura Ricerca Formazione e Innovazione, Dipartimento Attività Integrate Ricerca e Innovazione, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyHistopathology and Cytopathology Unit, Azienda Sanitaria Locale 5, 19121 La Spezia, ItalyLaboratory Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyOncology Division, Azienda Sanitaria Locale 5, 19121 La Spezia, ItalyMesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyMesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyMesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyLaboratory Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyRadiology Department, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyHistopathology and Cytopathology Unit, Azienda Sanitaria Locale 5, 19121 La Spezia, ItalyRadiodiagnostic Division, Azienda Sanitaria Locale 5, 19121 La Spezia, ItalyInfrastruttura Ricerca Formazione e Innovazione, Dipartimento Attività Integrate Ricerca e Innovazione, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyTumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyClinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyA soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker for diagnosis of pleural mesothelioma (PM) and the most used for monitoring treatment. Radiological assessment of PM, based on modified RECIST (mRECIST) criteria, is challenging. This pilot study was designed to evaluate whether SMRP levels correlated over time with mRECIST score. Serial serum samples from PM patients were collected and SMRP levels were measured and compared with the mRECIST score obtained through centralized CT scans by blinded review. The within-patient SMRP-mRECIST relationship over time was estimated through a normal random-effects regression approach applied to the log-transformed mRECIST score. Overall, 58 PM patients were included (46 males and 12 females) with a median age at diagnosis of 67 years (min–max = 48–79), 44 (76%) with epithelioid and 14 (24%) with non-epithelioid histology. The total number of SMRP measurements and CT scans considered for analysis was 183. There was a statistically significant correlation between SMRP and mRECIST score in the 2 cohorts considered both separately and jointly. These results, although exploratory, suggest that SMRP measurement might be considered as an adjunct to monitor PM patients in order to delay CT scans time interval, thus warranting further investigation.https://www.mdpi.com/2075-4418/11/11/2015mesotheliomamesothelinserum biomarkersmodified RECISTlongitudinal study |
| spellingShingle | Federica Grosso Matilde Mannucci Francesca Ugo Paola Ferro Maurizio Cassinari Antonella Vigani Antonina Maria De Angelis Sara Delfanti Michela Lia Roberto Guaschino Stefano Barbero Silvio Roncella Ugo Giannoni Marinella Bertolotti Maria Pia Pistillo Vincenzo Fontana Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score Diagnostics mesothelioma mesothelin serum biomarkers modified RECIST longitudinal study |
| title | Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score |
| title_full | Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score |
| title_fullStr | Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score |
| title_full_unstemmed | Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score |
| title_short | Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score |
| title_sort | pilot study to evaluate serum soluble mesothelin related peptide smrp as marker for clinical monitoring of pleural mesothelioma pm correlation with modified recist score |
| topic | mesothelioma mesothelin serum biomarkers modified RECIST longitudinal study |
| url | https://www.mdpi.com/2075-4418/11/11/2015 |
| work_keys_str_mv | AT federicagrosso pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT matildemannucci pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT francescaugo pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT paolaferro pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT mauriziocassinari pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT antonellavigani pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT antoninamariadeangelis pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT saradelfanti pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT michelalia pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT robertoguaschino pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT stefanobarbero pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT silvioroncella pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT ugogiannoni pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT marinellabertolotti pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT mariapiapistillo pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore AT vincenzofontana pilotstudytoevaluateserumsolublemesothelinrelatedpeptidesmrpasmarkerforclinicalmonitoringofpleuralmesotheliomapmcorrelationwithmodifiedrecistscore |